Barrington Research Estimates OPKO Health FY2025 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Barrington Research raised their FY2025 earnings per share estimates for shares of OPKO Health in a research report issued on Thursday, October 30th. Barrington Research analyst M. Petusky now expects that the biotechnology company will earn ($0.31) per share for the year, up from their previous estimate of ($0.41). Barrington Research has a “Outperform” rating and a $2.25 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Barrington Research also issued estimates for OPKO Health’s Q4 2025 earnings at ($0.05) EPS and FY2027 earnings at ($0.10) EPS.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $165.74 million. During the same quarter in the prior year, the business earned $0.03 EPS. The business’s revenue for the quarter was down 12.6% compared to the same quarter last year.

Several other brokerages have also recently commented on OPK. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Saturday. Jefferies Financial Group reiterated a “hold” rating and set a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a “strong-buy” rating in a research report on Tuesday, July 8th. Finally, Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $2.28.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.39 on Monday. The firm has a fifty day moving average of $1.46 and a two-hundred day moving average of $1.38. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -5.56 and a beta of 1.50. OPKO Health has a 52 week low of $1.11 and a 52 week high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently added to or reduced their stakes in OPK. Oak Thistle LLC bought a new position in shares of OPKO Health in the 1st quarter valued at about $26,000. GM Advisory Group LLC bought a new position in shares of OPKO Health in the 1st quarter valued at about $33,000. Cerity Partners LLC bought a new position in shares of OPKO Health in the 1st quarter valued at about $36,000. Arrow Financial Corp bought a new position in shares of OPKO Health in the 3rd quarter valued at about $39,000. Finally, Fisher Asset Management LLC bought a new position in shares of OPKO Health in the 2nd quarter valued at about $40,000. Institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The shares were acquired at an average price of $1.42 per share, with a total value of $213,000.00. Following the purchase, the chief executive officer owned 214,386,448 shares of the company’s stock, valued at $304,428,756.16. This represents a 0.07% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 49.69% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.